On December 26, 2025, the Phase I/II clinical trial launch meeting for GC310 adeno-associated virus (AAV) injection, an AAV gene therapy drug independently developed by Beijing Genecradle Therapeutics Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics"), for the treatment of Wilson disease (WD), was held at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences. The meeting was attended by Professor Qiu Zhengqing and Professor Han Xiaohong, the principal investigators of the research center at PUMCH, together with core members of their research teams, representatives from the Good Clinical Practice (GCP) Office of the Clinical Pharmacology Research Center, clinical operations and medical affairs representatives from the sponsor Genecradle Therapeutics, and members of the Safety Monitoring Committee.

This study is a nationwide, multi-center, open-label, single-dose, dose-escalation clinical trial designed to evaluate the safety and tolerability of GC310 intravenous injection in patients with Wilson disease. The trial plans to enroll 10–15 adult patients with Wilson disease. During the launch meeting, participants engaged in comprehensive discussions covering project status, study protocol, clinical operational procedures, and monitoring plans to ensure the smooth conduct of the clinical trial. The research center at PUMCH and the sponsor Genecradle Therapeutics will uphold shared objectives, strictly adhere to GCP standards, implement refined management to rigorously control trial quality, and efficiently advance this clinical trial, striving to bring benefits to more patients with Wilson disease at the earliest opportunity.